Healthpeak Properties, Inc. (DOC) fair value analysis
S&P 500 · Updated 2026-10-19
DOC price how computed
Valuation status
No P/E-based verdictDOC: P/E-based fair value does not apply to REITs; their earnings are reported net of depreciation.
The price, fundamentals and dividend data below are unaffected.
- Last price
- $18.80
- Sector
- Real Estate
- 12-month range
- $15.78–$22.82
- Market cap
- $13B
- From 52-week high
- -17.6%
- Shares outstanding
- 690M
- Rank in Real Estate by quality score
- #11 of 45
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Healthpeak Properties, Inc. is a real estate investment trust that owns and operates medical office buildings, senior housing communities, and life science properties. The company operates across the United States with a focus on healthcare real estate in major metropolitan markets.
DOC currently ranks #11 of 45 Real Estate stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $13B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $2.95B
- Net margin
- 8.6%
- EPS (TTM)
- $0.66
- Gross margin
- 56.8%
- Debt / equity
- 1.32
- Revenue growth (3-yr avg)
- 12.9%
- Shares outstanding
- 690M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 35 · neutral
- 50-day average
- $20.28
- 200-day average
- $19.02
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $1.22 per share (12 payments)
- Yield on last price
- 6.49%
- Consecutive years of increases
- 1
- Next ex-dividend date
- 2026-11-13
- Last payment date
- 2026-10-30
Earnings how computed
- Next earnings report
- 2026-11-02 (post-market)
- Last 8 quarters vs consensus
- 4 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.5%)
2026-03 ▲ beat (+366.7%)
2025-12 ▲ beat (+66.7%)
2025-09 ▼ miss (-400.0%)
2025-06 ▬ met (0.0%)
2025-03 ▲ beat (+20.0%)
2024-12 ▬ met (0.0%)
2024-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 14 hold · 0 sell (22 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $22.9
- Target vs last price
- +21.8%
What our data shows for DOC
- Shares are trading in the middle of their 12-month price range of $15.78–$22.82.
- The 14-day relative strength index sits at a neutral 35.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- DOC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent DOC news
TickrTrends' derived news-sentiment signal for DOC is currently mixed, computed from recent coverage.
- DOC Maintained by Wells Fargo -- Price Target Lowered to $19.00 (gurufocus.com, 2026-10-19)
- Healthpeak Properties Inc's Dividend Analysis (gurufocus.com, 2026-10-19)
- DOC Maintained by Barclays -- Price Target Lowered to $21.00 (gurufocus.com, 2026-10-13)
What people are saying
Follow the DOC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for DOC show that the real estate investment trust's quality grade improved from D to C this week. As a REIT, DOC does not receive a P/E-based valuation verdict from TickrTrends' standard methodology. The upgrade in quality metrics reflects positive movement in the company's fundamental indicators tracked by the service.
- 2026-10-06 — TickrTrends' derived indicators for DOC showed a change in valuation assessment this week. The previous valuation verdict of Overvalued was replaced with no P/E-based verdict due to DOC's classification as a Real Estate Investment Trust, which uses different valuation metrics than traditional equities.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is DOC stock undervalued?
TickrTrends publishes no fair-value verdict for DOC. P/E-based fair value does not apply to REITs; their earnings are reported net of depreciation.
What is DOC's TickrTrends verdict?
DOC is a REIT, so it is marked 'No P/E-based verdict'. Its price, fundamentals and dividend data are still shown and refreshed with every run.
How does DOC compare to other Real Estate stocks?
DOC ranks #11 of 45 Real Estate stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is DOC overbought or oversold?
DOC's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does DOC pay a dividend?
Yes. DOC paid $1.22 per share over the last twelve months (12 payments), a 6.49% yield on TickrTrends' last price, and has raised the annual total for 1 consecutive year. The next ex-dividend date on file is 2026-11-13.
When does DOC report earnings next?
DOC's next earnings report is scheduled for 2026-11-02 (post-market), per the published earnings calendar.
Does DOC usually beat earnings estimates?
Over its last 8 reported quarters DOC beat the consensus estimate 4 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DOC?
Of 22 analysts covering DOC, 8 rate it a buy, 14 a hold and 0 a sell - hold-leaning, with a consensus price target of $22.9 (+21.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.